Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Heterozygous TREM2 mutations are an Alzheimer’s disease (AD) risk factor. Non-mutated TREM2 dysregulation occurs in AD brain. Whether TREM2 is altered in prodromal AD remains unknown. Western blotting was used to determine levels of TREM2 (~ 25 kDa) and Iba1 in the frontal cortex and TREM2 in the hippocampus, two structures early affected by amyloid plaque and neurofibrillary tangle (NFT) pathology, respectively, from people who died with an ante-mortem clinical diagnosis of non- and mild-cognitive impairment, mild/moderate AD (mAD) and severe AD (sAD). Immunohistochemistry defined the relationship between amyloid and Iba1 profiles. PCR analysis revealed that all subjects did not carry the most common R47H TREM2 variant. TREM2 was significantly upregulated in sAD frontal cortex, but stable in hippocampus. Frontal TREM2 mRNA and protein level patterns were similar, but not significantly different. Iba1 immunopositive microglia counts increased significantly in frontal cortex containing plaques in sAD. TREM2 and Iba1 levels were not associated with plaques, tangles, neuropathological criteria or cognitive performance. Frontal cortex TREM2 upregulation is a late event and may not play a major role early in the pathogenesis of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“Recent neuropathological guidelines for AD require the transactive response DNA-binding protein of 43 kDa (TDP-43) inclusions (Montine et al., 2012).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 4×
“Individuals harboring the heterozygous missense mutation (rs75932628) in exon 2 of TREM2 in which arginine substitutes for histidine at residue 47 (R47H) display an increased risk for AD (Benitez et al., 2013; Guerreiro et al., 2013b; Jonsson et al., 2013; Pottier et al., 2013; Slattery et al., 2014).”
BackgroundInfluentialNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“…of the number of neuritic plaques (NPs), diffuse plaques (DPs), and NFTs were performed in a one square mm area (100x magnification) per neocortical region by a board-certified neuropathologist or trained technician blinded to all clinical data (Bennett et al., 2004, 2006; Mufson et al., 2012).”
MethodTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111 · cited 2×
“TREM2 is expressed exclusively in microglia (Colonna, 2003; Lue et al., 2015; Takahashi et al., 2005) and regulates inflammation and phagocytosis (Neumann et al., 2009).”
BackgroundYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · cited 2×
“, 2015), which seems to be impaired in the TREM2 R47H variant (Wang et al., 2015; Yeh et al., 2016).”
BackgroundTREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 1×
“TREM2 or DAP12 deficiency leads to an increase in plaques not fully enclosed by microglial and dystrophic profiles (Wang et al., 2016; Yuan et al., 2016).”
BackgroundThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Cited by
Risk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Metadata
- Authors
- Perez, S. E., Nadeem, M., He, B., Miguel, J. C., Malek-Ahmadi, M. H., Chen, K., & Mufson, E. J.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 54
- Pages
- 133-143
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2594292536
- Cited by
- 49
- References
- 33
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2017.02.012
- The paper
- Perez, S. E., Nadeem, M., He, B., Miguel, J. C., Malek-Ahmadi, M. H., Chen, K., & Mufson, E. J. (2017). Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2017.02.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.